Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 9/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5211995 | 0.84 | AVPR1A (0.57) | AVPR1AKDM4E | |
| SCHEMBL5216561 | 0.80 | AVPR1A (0.74) | AVPR1AKDM4E | |
| SCHEMBL5213482 | 0.80 | AVPR1A (0.62) | AVPR1AKDM4E | |
| SCHEMBL5214733 | 0.78 | AVPR1A (0.70) | AVPR1AKDM4E | |
| SCHEMBL5212430 | 0.78 | AVPR1A (0.57) | AVPR1AKDM4E | |
| SCHEMBL5212360 | 0.77 | AVPR1A (0.80) | AVPR1AKDM4E | |
| SCHEMBL5215700 | 0.76 | AVPR1A (0.78) | AVPR1A | |
| SCHEMBL5211608 | 0.74 | AVPR1A (0.84) | AVPR1AKDM4E | |
| SCHEMBL5213359 | 0.73 | AVPR1A (0.60) | AVPR1AKDM4E | |
| SCHEMBL5211759 | 0.73 | AVPR1A (0.58) | AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558598-B1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LTD (GB) | 2007-07-18 | — | — | EP | claimed |
| US-7084145-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2006-08-01 | — | — | US | claimed |
| US-20040162278-A1 | Triazole compounds useful in therapy | PFIZER INC | 2004-08-19 | — | — | US | claimed |
| EP-1656183-B1 | TREATMENT OF MALE SEXUAL DYSFUNCTION | PFIZER LTD (GB) | 2007-12-05 | — | — | EP | disclosed |
| EP-1558598-B1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LTD (GB) | 2007-07-18 | — | — | EP | disclosed |
| US-7084145-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1656183-A1 | TREATMENT OF MALE SEXUAL DYSFUNCTION | Pfizer Limited (GB) | 2006-05-17 | — | — | EP | disclosed |
| EP-1558598-A1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | Pfizer Limited (GB) | 2005-08-03 | — | — | EP | disclosed |
| US-20050026810-A1 | Treatment of male sexual dysfunction | PFIZER INC. | 2005-02-03 | — | — | US | disclosed |
| WO-2005006899-A1 | TREATMENT OF MALE SEXUAL DYSFUNCTION | PFIZER LIMITED (GB) | 2005-01-27 | — | — | WO | disclosed |
| US-20040162278-A1 | Triazole compounds useful in therapy | PFIZER INC | 2004-08-19 | — | — | US | disclosed |
| WO-2004037809-A1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162278-A1 | Triazole compounds useful in therapy | AVPR2, AVPR1B, AVPR1A | AVPR1A 3/4885KDM4E 4654/4885DRD2 204/4885 |
| US-20050026810-A1 | Treatment of male sexual dysfunction | AVPR1A, AVPR1B, AVPR2 | AVPR1A 1/4885KDM4E 1838/4885DRD2 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.